Established giants such as Pfizer and Genentech dominated this year’s annual meeting of the American Society of Clinical Oncology (ASCO). But the meeting is also a great place to scout out small biotechs and promising drugs. The following treatments may not be quite ready for prime time--either for investors or patients--but they’re at least worth keeping an eye on.
